Actively Recruiting
Effects of miR-342-5p/AnkG Pathway-Mediated Axon Initial Segment Filtering Injury on Early Synaptic Dysfunction in Alzheimer's Disease and Its Clinical Applications
Led by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Updated on 2026-01-20
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Alzheimer's disease is the most common cause of memory loss in older adults, affecting memory, language, attention, and behavior. Researchers are investigating early changes in brain nerve cell connections that may lead to these symptoms. This study focuses on a specific pathway called miR-342-5p/AnkG, which previous research suggests may be involved in these early brain changes and can be detected in blood and cerebrospinal fluid. The goal is to better understand these mechanisms and find biomarkers for early disease detection. Participants include people diagnosed with probable Alzheimer's disease and healthy individuals of similar age. The study involves collecting peripheral blood samples and, if participants agree, cerebrospinal fluid samples as well. Two groups are studied: one with Alzheimer's disease and one healthy control group. The research team will analyze these samples to explore the relationship between the miR-342-5p/AnkG pathway and synaptic proteins. During the 12 weeks after enrollment, participants will undergo assessments to measure the correlation between the pathway and synaptic proteins, cognitive function, and brain changes such as atrophy. Brain MRI scans and neurological exams are also part of the evaluation. This study aims to provide new insights for early diagnosis and better understanding of Alzheimer's disease progression.
CONDITIONS
Brief Title
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the diagnostic criteria for probable Alzheimer's disease dementia (NINCDS-ADRDA) for the AD group
- MMSE score between 0-23 points, CDR score of 0.5 or higher, and Hachinski Ischemic Score less than 4 for the AD group
- Brain MRI showing bilateral temporal lobe and hippocampal atrophy for the AD group
- Age 50 years or older
- Healthy subjects age-matched to the AD group for the control group
- Normal cognitive function and good daily living activities for the control group
- No dementia among first-degree relatives for the control group
- Negative brain MRI and neurological exam for the control group
You will not qualify if you...
- Dementia or cognitive impairment caused by other diseases
- History of substance abuse
- Progressive primary aphasia
- Previous traumatic brain injury
- Comorbid depression, schizophrenia, or severe cardiovascular, hepatic, renal, or hematological diseases
- Impaired consciousness or inability to cooperate
- Other conditions unsuitable for inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 weeks after enrollment
Participants provide peripheral blood samples and, if they consent, cerebrospinal fluid samples to evaluate the miR-342-5p/AnkG pathway and its relation to synaptic dysfunction in early Alzheimer's disease.
1 to 2 visits depending on consent for cerebrospinal fluid collection
Duration - Up to 12 weeks after enrollment
Participants are monitored for correlations between the miR-342-5p/AnkG pathway, cognitive function, and brain atrophy.
Follow-up assessments during the 12-week period
Trial Site Locations
Total: 1 location
1
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, China, 322000
Actively Recruiting
Research Team
X
Xu-hua Xu
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here